We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

By LabMedica International staff writers
Posted on 29 Apr 2024

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. More...

Although no cure exists currently, the effectiveness of emerging therapies might depend on early detection and slowing the disease's progression before severe debilitation occurs. Traditional diagnostic methods typically do not catch the disease until it has already caused structural damage to the joint. For example, an abnormal X-ray can reveal definitive signs of knee OA, but by the time these signs are visible, the disease has often been advancing for years. Now, a novel blood test has been developed that can predict the onset of knee OA at least eight years before its signs become visible on X-rays.

Researchers at Duke Health (Durham, NC, USA) validated the accuracy of the blood test, which detects key biomarkers of OA. Their findings indicate that the test not only predicts the onset of OA but also its progression, a capability demonstrated in prior studies. The focus of their research has been on identifying molecular biomarkers usable in clinical diagnostics and as tools for drug development research. Previously, the blood biomarker test proved to be 74% accurate in predicting the progression of knee OA and 85% accurate in diagnosing the condition.

In the current study, the team improved the test's predictive capabilities. Utilizing a comprehensive database from the United Kingdom, the team examined the serum from 200 white women, with half being diagnosed with OA and the other half without, matched for body mass index and age. They found a small number of biomarkers in the blood test that effectively differentiated those with knee OA from those without the condition, detecting molecular signals of OA up to eight years before the women received an OA diagnosis via X-ray.

“What our blood test demonstrates is that it’s possible to detect this disease much earlier than our current diagnostics permit,” said Virginia Byers Kraus, M.D., Ph.D., a professor at Duke University School of Medicine. “Early-stage osteoarthritis could provide a ‘window of opportunity’ in which to arrest the disease process and restore joint health.”

Related Links:
Duke Health


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
New
Pipette
Accumax Smart Series
New
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.